Search the Newsreel

Ultrapar Participacoes S.A. (NYSE:UGP) Short Interest Update

Ultrapar Participacoes S.A. (UGP) saw a significant increase in short interest, more than doubling to 2.46 million shares in July, though this still represents only about 0.2% of its shares. Despite this, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an …

Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO

Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics …

Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from …

How (ADXN) Movements Inform Risk Allocation Models

This article analyzes Addex Therapeutics Ltd (NASDAQ: ADXN), highlighting a positive near-term sentiment but broader weak alignment. It presents an exceptional 60.0:1 risk-reward setup targeting a 20.6% gain against a 0.3% risk. The article outlines institutional trading strategies, including position trading, momentum breakout, and …

C4 Therapeutics (CCCC) gains 6.9% disclosed stake from Squadron Master Fund

Squadron Master Fund LP and related entities have disclosed a 6.9% beneficial ownership stake in C4 Therapeutics (CCCC), totaling 7,600,000 shares. This includes 7,200,000 common shares and 400,000 shares underlying currently exercisable long call options. The filing indicates shared voting and dispositive powers among …

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen has downgraded Protara Therapeutics (NASDAQ:TARA) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy" with an average price target of $26.25. The company's shares were trading at $3.97, near their 52-week low, after reporting …

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Candel Therapeutics (NASDAQ:CADL) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $19.29, significantly above its current trading price of $11.72. Despite recent insider share sales and a larger-than-expected quarterly loss of $0.52 per share, analysts maintain …

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Enliven Therapeutics (NASDAQ:ELVN) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $72.67. This comes despite the company reporting a wider-than-expected quarterly loss of $0.49 per share. Recent insider selling, including a director's $9.6 million sale, has …

KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock information for Kailera Therapeutics, Inc. (KLRA), including its real-time price, key market data like market cap and trading volume, and historical performance trends. It details how to buy KLRA stock on the MEXC exchange and offers an overview of …

Silence Therapeutics closes $201.3M public offering By Investing.com

Silence Therapeutics plc (NASDAQ:SLN) has successfully closed an underwritten public offering, raising approximately $201.3 million. The offering included 14,907,407 American Depositary Shares at $13.50 per ADS, with underwriters fully exercising their option for additional shares. The gross proceeds will support the clinical-stage biotechnology company …

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts

Gain Therapeutics (NASDAQ:GANX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $7.50. The company recently reported a narrower-than-expected quarterly loss of $0.11 per share. Institutional investors hold a significant portion of GANX stock, with several firms …

Assenagon Asset Management S.A. Acquires 87,178 Shares of Rapid7, Inc. $RPD

Assenagon Asset Management S.A. significantly increased its stake in Rapid7, Inc. (NASDAQ:RPD) by 113.7% in the second quarter, acquiring an additional 87,178 shares to bring its total to 163,844 shares valued at approximately $1.33 million. Despite the company exceeding quarterly earnings and revenue expectations, …

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss …

Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN

Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Viking Therapeutics Inc (VKTX) News, Articles, Events & Latest Updates

Are Capricor Therapeutics’ (CAPR) Rising Losses Reframing the Risk-Reward Balance of Its Pipeline Strategy?

Liquidity Mapping Around (APGE) Price Events

This article provides a detailed liquidity mapping analysis for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies including long, momentum breakout, and short positions with specific entry, target, and stop-loss levels. …

T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G

T. Rowe Price Associates, Inc. has disclosed a 5.2% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN) through a Schedule 13G SEC filing. As of June 30, 2026, the firm holds 5,748,426 shares of common stock, with sole voting power over 5,748,380 shares and …

Nouveau Monde Graphite (NYSE:NMG) Upgraded to Hold at Wall Street Zen

Wall Street Zen has upgraded Nouveau Monde Graphite (NYSE:NMG) from a "sell" to a "hold" rating. Despite this, MarketBeat indicates a consensus "Moderate Buy" rating with an average price target of $4.67 for the stock. NMG shares opened at $1.47, near their 52-week low, …

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics (OTLK) stock has seen a significant decline over the past five years, despite the recent FDA approval and upcoming launch of LYTENAVA. The company's valuation scores poorly, indicating it's not a bargain, and its balance sheet shows a negative book value, making …

Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold

Wall Street Zen has upgraded Cardiol Therapeutics (NASDAQ:CRDL) from a "Sell" to a "Hold" rating, aligning with the overall average "Hold" rating from analysts and an $8.50 price target. CRDL shares rose 5.3% to $1.80, with a market cap of $208.6 million, and the …

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen

Wall Street Zen has upgraded Unicycive Therapeutics (NASDAQ:UNCY) from a "sell" to a "hold" rating, contributing to a mixed analyst consensus of "Hold" with a $18.25 price target. Despite several firms like Benchmark and HC Wainwright maintaining bullish ratings but cutting price targets, and …

Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?

Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen

Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded Maze Therapeutics (NASDAQ:MAZE) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $66.00. The company's shares opened at $27.18, representing a 1.8% decrease and significantly below its 52-week high …

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Lexeo Therapeutics (NASDAQ:LXEO) from a "hold" to a "strong sell" rating, despite a broader analyst consensus of "Buy" with an average price target of $18.75. The company's shares opened at $4.84, near its 12-month low, and it reported a …

Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen has downgraded Relay Therapeutics (NASDAQ:RLAY) from a "Hold" to a "Sell" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $25.83. This downgrade follows the company's recent quarterly earnings report, where it missed both …

Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded Neumora Therapeutics (NASDAQ:NMRA) from a "strong sell" to a "sell" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $6.57. NMRA shares recently dropped by 7.5%, opening at $1.60, and the company reported …

Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts

Apogee Therapeutics Inc. (NASDAQ:APGE) has received a consensus "Hold" rating from analysts, with 15 out of 20 firms issuing hold ratings. The average 12-month price target is $124.43, while the stock recently opened at $134.55. The company reported a quarterly loss of $1.14 per …

Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Sionna Therapeutics (NASDAQ:SION) to a "strong sell" rating. This comes amidst broader analyst sentiment leaning towards "hold," with the stock opening significantly below its 52-week high and reporting a quarterly loss that missed estimates. Insider selling has occurred, though some …

Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen

Wall Street Zen has upgraded Ovid Therapeutics (NASDAQ:OVID) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with a target price of $5.71. The company recently reported a quarterly loss of $0.08 per share, outperforming expectations, and …

Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen

Wall Street Zen downgraded Mineralys Therapeutics (NASDAQ:MLYS) to "Strong Sell" following a significant second-quarter earnings miss, where the company lost $2.85 per share against an expected $0.55 loss. Despite this, the broader analyst consensus remains a "Moderate Buy" with a $49.33 price target. Insider …

Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Tenax Therapeutics (NASDAQ:TENX) from a "sell" to a "strong sell" rating. This comes amidst other analysts also reducing their ratings, though the broader consensus remains a "Moderate Buy" with a $14 average price target. The company, which is developing pain-management …

ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded ADC Therapeutics (NYSE:ADCT) from a "sell" to a "hold" rating. The company reported a quarterly loss of $0.11 per share, beating analyst estimates, with revenue of $19.25 million also exceeding expectations. Despite mixed analyst coverage, the stock has a consensus …

Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear

Outlook Therapeutics (OTLK) stock has declined significantly over the past five years, yet recent valuation checks do not indicate it is a clear bargain. The company's negative shareholder equity makes its Price-to-Book (P/B) ratio unreliable for valuation, and despite the recent approval of LYTENAVA …